What is the share price of Alpa Laboratories Ltd (ALPA) today?
The share price of ALPA as on 18th September 2026 is ₹59.35. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alpa Laboratories Ltd (ALPA) share?
The past returns of Alpa Laboratories Ltd (ALPA) share are- Past 1 week: -5.31%
- Past 1 month: -7.34%
- Past 3 months: -12.54%
- Past 6 months: -1.03%
- Past 1 year: -37.08%
- Past 3 years: -18.87%
- Past 5 years: 13.81%
What are the peers or stocks similar to Alpa Laboratories Ltd (ALPA)?
The peers or stocks similar to Alpa Laboratories Ltd (ALPA) include:What is the market cap of Alpa Laboratories Ltd (ALPA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alpa Laboratories Ltd (ALPA) is ₹124.88 Cr as of 18th September 2026.What is the 52 week high and low of Alpa Laboratories Ltd (ALPA) share?
The 52-week high of Alpa Laboratories Ltd (ALPA) is ₹95.95 and the 52-week low is ₹46.10.What is the PE and PB ratio of Alpa Laboratories Ltd (ALPA) stock?
The P/E (price-to-earnings) ratio of Alpa Laboratories Ltd (ALPA) is 8.32. The P/B (price-to-book) ratio is 0.73.Which sector does Alpa Laboratories Ltd (ALPA) belong to?
Alpa Laboratories Ltd (ALPA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alpa Laboratories Ltd (ALPA) shares?
You can directly buy Alpa Laboratories Ltd (ALPA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alpa Laboratories Ltd
ALPA Share Price
NSE₹59.350.70% (-0.42)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ALPA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ALPA Performance & Key Metrics
ALPA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.76 | 0.73 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
ALPA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ALPA Company Profile
Alpa Laboratories Limited is a pharmaceutical company. The Company operates in the drugs and chemicals segment.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
ALPA Forecast
ALPA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ALPA
ALPA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ALPA Income Statement
ALPA Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 27.59 | 26.60 | 31.85 | 34.95 | 42.40 | 31.06 | 29.32 | 29.96 | 31.24 | 29.70 | ||||||||||
Operating & Other expenses | 20.10 | 20.91 | 21.62 | 25.41 | 39.72 | 18.69 | 28.50 | 27.54 | 27.80 | 27.89 | ||||||||||
EBITDA | 7.49 | 5.69 | 10.23 | 9.54 | 2.68 | 12.37 | 0.82 | 2.42 | 3.44 | 1.81 | ||||||||||
| Depreciation/Amortization | 0.52 | 0.54 | 0.53 | 0.55 | 0.58 | 0.55 | 0.67 | 0.65 | 0.22 | 0.72 | ||||||||||
| PBIT | 6.97 | 5.15 | 9.70 | 8.99 | 2.10 | 11.82 | 0.15 | 1.77 | 3.22 | 1.09 | ||||||||||
| Interest & Other Items | 0.29 | 0.05 | 0.05 | 0.09 | 0.02 | 0.05 | 0.03 | 0.03 | 0.15 | 0.11 | ||||||||||
| PBT | 6.68 | 5.10 | 9.65 | 8.90 | 2.08 | 11.77 | 0.12 | 1.74 | 3.07 | 0.98 | ||||||||||
| Taxes & Other Items | 3.12 | 0.00 | 1.96 | 0.00 | 4.20 | 0.00 | 0.00 | 0.16 | 1.69 | 0.00 | ||||||||||
| Net Income | 3.56 | 5.10 | 7.69 | 8.90 | -2.12 | 11.77 | 0.12 | 1.58 | 1.38 | 0.98 | ||||||||||
| EPS | 1.71 | 2.42 | 3.66 | 4.23 | -0.95 | 5.59 | 0.05 | 0.76 | 0.24 | 0.49 |
ALPA Company Updates
ALPA Stock Peers
ALPA Past Performance & Peer Comparison
ALPA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alpa Laboratories Ltd | 8.32 | 0.73 | — |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
ALPA Stock Price Comparison
Compare ALPA with any stock or ETFCompare ALPA with any stock or ETF
ALPA
ALPA Holdings
ALPA Shareholdings
ALPA Promoter Holdings Trend
ALPA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ALPA Institutional Holdings Trend
ALPA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ALPA Shareholding Pattern
ALPA Shareholding Pattern
ALPA Shareholding History
ALPA Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ALPA stock
smallcases containing ALPA stock
Looks like this stock is not in any smallcase yet.
ALPA Events
ALPA Events
ALPA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALPA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ALPA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALPA has not given any dividends in last 5 years
ALPA Dividends
ALPA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeALPA Stock News & Opinions
ALPA Stock News & Opinions
Articles & Videos
Earnings
Earnings
Alpa Laboratories reports consolidated net profit of Rs 1.38 crore in the March 2026 quarterNet profit of Alpa Laboratories reported to Rs 1.38 crore in the quarter ended March 2026 as against net loss of Rs 2.12 crore during the previous quarter ended March 2025. Sales declined 21.34% to Rs 31.40 crore in the quarter ended March 2026 as against Rs 39.92 crore during the previous quarter ended March 2025. For the full year,net profit declined 23.03% to Rs 15.01 crore in the year ended March 2026 as against Rs 19.50 crore during the previous year ended March 2025. Sales declined 5.90% to Rs 105.81 crore in the year ended March 2026 as against Rs 112.45 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales31.4039.92 -21 105.81112.45 -6 OPM %11.460.48 -3.114.22 - PBDT3.292.66 24 18.7927.87 -33 PBT3.072.08 48 16.7025.67 -35 NP1.38-2.12 LP 15.0119.50 -23 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Alpa Laboratories to declare Quarterly ResultsAlpa Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2026.
4 months agoCapital Market - Live
Earnings
Earnings
Alpa Laboratories consolidated net profit declines 78.65% in the December 2025 quarterNet profit of Alpa Laboratories declined 78.65% to Rs 1.90 crore in the quarter ended December 2025 as against Rs 8.90 crore during the previous quarter ended December 2024. Sales rose 11.09% to Rs 29.05 crore in the quarter ended December 2025 as against Rs 26.15 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales29.0526.15 11 OPM %5.202.83 - PBDT2.399.45 -75 PBT1.758.90 -80 NP1.908.90 -79 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Alpa Laboratories to declare Quarterly ResultsAlpa Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Alpa Laboratories consolidated net profit declines 98.57% in the September 2025 quarterNet profit of Alpa Laboratories declined 98.57% to Rs 0.11 crore in the quarter ended September 2025 as against Rs 7.69 crore during the previous quarter ended September 2024. Sales rose 5.29% to Rs 26.26 crore in the quarter ended September 2025 as against Rs 24.94 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales26.2624.94 5 OPM %-8.5313.31 - PBDT0.7810.18 -92 PBT0.119.65 -99 NP0.117.69 -99 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Alpa Laboratories schedules board meetingAlpa Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Alpa Laboratories to conduct AGMAlpa Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Earnings
Earnings
Alpa Laboratories consolidated net profit rises 130.78% in the June 2025 quarterNet profit of Alpa Laboratories rose 130.78% to Rs 11.77 crore in the quarter ended June 2025 as against Rs 5.10 crore during the previous quarter ended June 2024. Sales declined 10.87% to Rs 19.11 crore in the quarter ended June 2025 as against Rs 21.44 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales19.1121.44 -11 OPM %2.252.47 - PBDT12.325.64 118 PBT11.775.10 131 NP11.775.10 131 Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Corporate
Alpa Laboratories to conduct board meetingAlpa Laboratories will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Earnings
Earnings
Alpa Laboratories reports consolidated net loss of Rs 2.12 crore in the March 2025 quarterNet loss of Alpa Laboratories reported to Rs 2.12 crore in the quarter ended March 2025 as against net profit of Rs 3.55 crore during the previous quarter ended March 2024. Sales rose 69.08% to Rs 39.92 crore in the quarter ended March 2025 as against Rs 23.61 crore during the previous quarter ended March 2024. For the full year,net profit rose 16.21% to Rs 19.50 crore in the year ended March 2025 as against Rs 16.78 crore during the previous year ended March 2024. Sales rose 3.41% to Rs 112.45 crore in the year ended March 2025 as against Rs 108.74 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales39.9223.61 69 112.45108.74 3 OPM %0.4814.87 -4.227.46 - PBDT2.667.18 -63 27.8722.64 23 PBT2.086.65 -69 25.6720.68 24 NP-2.123.55 PL 19.5016.78 16 Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 3.58%, vs industry avg of 11.76%
Over the last 5 years, market share decreased from 0.04% to 0.02%
Over the last 5 years, net income has grown at a yearly rate of 15.7%, vs industry avg of 10.45%